Werewolf Therapeutics announces USD 150 million oversubscribed private placement of shares, pre-funded warrants
HOWL•Proceeds to fund operations into 1H 2029
Proceeds are slated to fund operations into 1H 2029, covering Phase 3 CRPS-RISE topline results expected in 2028.
The funding also supports a planned NDA submission for neridronate in CRPS-1, a condition with no FDA-approved therapy.
Oversubscribed private placement alongside Ambros merger
Werewolf Therapeutics disclosed an oversubscribed private placement raising USD 150 million alongside its planned all-stock merger with Ambros.
Financing is expected to close with the merger through issuance of common stock and pre-funded warrants.
